IPVS policy statement on HPV nucleic acid testing guidance for those utilising/considering HPV as primary precancer screening: Quality assurance and quality control issues.
J Clin Virol
; 159: 105349, 2023 Feb.
Article
in English
| MEDLINE | ID: covidwho-2231219
ABSTRACT
We advise that only clinically validated HPV assays which have fulfilled internationally accepted performance criteria be used for primary cervical screening. Further, assays should be demonstrated to be fit for purpose in the laboratory in which they will ultimately be performed, and quality materials manuals and frameworks will be helpful in this endeavor. Importantly, there is a fundamental shortage of well validated, low-cost, low complexity HPV tests that have demonstrated utility in a near-patient setting; representing a significant challenge and focus for future development in order to reach the WHO's goal of eliminating cervical cancer.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Nucleic Acids
/
Uterine Cervical Neoplasms
/
Papillomavirus Infections
Type of study:
Diagnostic study
/
Prognostic study
Limits:
Female
/
Humans
Language:
English
Journal:
J Clin Virol
Journal subject:
Virology
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS